Is the beneficial antidepressant effect of coadministration of pindolol really due to somatodendritic autoreceptor antagonism?

Biological Psychiatry

Volumn 50, Issue 1, 2001, Pages 13-21

  Cremers, Thomas I F H ^a   Wiersma, Loes J ^a   Bosker, Fokko J ^b   Den Boer, Johan A ^b   Westerink, Ben H C ^a   Wikström, Håkan V ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

5 HT1A; Guinea pig; Microdialysis; Paroxetine; Pindolol; SSRI

Indexed keywords

AUTORECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC AMP; ISOPRENALINE; PAROXETINE; PINDOLOL; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CATHETERIZATION; CELL LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFECT; GUINEA PIG; HIPPOCAMPUS; JUGULAR VEIN; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING;

ANIMALS; ANTIDEPRESSIVE AGENTS; AUTORECEPTORS; BRAIN; CYCLIC AMP; GUINEA PIGS; HIPPOCAMPUS; MAGNETIC RESONANCE IMAGING; MALE; PAROXETINE; PINDOLOL; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; SYNAPTIC TRANSMISSION; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035394019     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(00)01093-3     Document Type: Article

References (37)

1. Regional distribution of extracellular 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in the brain of freely moving rats
2. Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography
3. 5-HT and antidepressants: New views from microdialysis studies
4. Clinical pharmacokinetics of citalopram and other selective serotonergic reuptake inhibitors (SSRI)
5. In vitro selectivity of agonists and antagonists for beta1- and beta 2-adrenoceptor subtypes in rat brain
6. Binding of β-adrenoceptor blocking drugs to human serum albumin, to α1-acid glycoprotein and to human serum
7. Current advances and trends in the treatment of depression
8. Modifications of the serotonin system by antidepressant treatments: Implications for the therapeutic response in major depression
9. 1A receptors: Variations in intrinsic activity studied in transfected HeLa cells
10. Relationship between the inhibition constant (Ki) and the conentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction
11. Electrophysiological evidence for a large receptor reserve for inhibition of dorsal raphe neuronal firing by 5-HT1A antagonists
12. 1B receptor antagonist critically depends on the dose of citalopram
13. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness
14. Stimulation and inhibition of adenylyl cyclase by distinct 5-hydroxytryptamine receptors
15. Enhancement of fluoxetine-dependent increase of extracellular serotonin (5-HT) levels by (-)-pindolol, an antagonist at 5-HT1A receptors
16. Use of microdialysis to measure brain noradrenergic receptor function in vivo
17. Pindolol suppresses serotonergic neuronal activity and does not block the inhibition of serotonergic neurons produced by 8-hydroxy-2-(di-n-propylamino)tetralin in awake cats
18. Stereoselective determination of plasma pindolol in endotoxin-pretreated rats by high-performance liquid chromatography
19. (-)-Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine
20. WAY100635-induced augmentation of the 5-HT-elevating action of citalopram: Relative importance of the dose of the 5-HT1A (auto)receptor blocker versus that of the 5-HT reuptake inhibitor
21. Pindolol augmentation of antidepressant therapy
22. In vivo calibration of microdialysis probes for exogenous compounds
23. Effects of milnacipran and pindolol on extracellular noradrenaline and serotonin levels in guinea pig hypothalamus
24. Augmentation strategies in depression 2000
25. 1A) receptors
26. Metabolism of pindolol in patients with renal failure
27. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors
28. Pharmacological differentiation and characterisation of 5-HT1A, 5-HT1B and 5-HT1C binding sites in rat frontal cortex
29. Chronic treatment with citalopram induces noradrenaline receptor hypoactivity. A microdialysis study
30. Displacement of the binding of 5-HT1A receptor ligands to pre- and postsynaptic receptors by (-)pindolol. A comparative study in rodent, primate and human brain
31. Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors: In vivo microdialysis and electrophysiological studies in the rat brain
32. Characterization of the in vivo release of dopamine as recorded by different types of intracerebral microdialysis probes
33. 1A agonist activity of pindolol: Reversal of the inhibitory effects on cell firing in the dorsal raphe nucleus but not in the hippocampus by WAY-100,635
34. Determination of adenosine and cyclic adenosine monophosphate in urine using solid-phase extraction and high-perfomance liquid chromatography with fluorimetric detection
35. 1D receptors